Study guide

6.1 Acute Coronary Syndromes: STEMI & NSTE-ACS Pharmacotherapy

BCEMP Board Certified Emergency Medicine Pharmacist Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction, Triage, and Resuscitation Fundamentals

1.1 BCEMP Exam Logistics, Content Outlines & Scoring 1.2 Emergency Triage Systems (ESI) & Pre-Hospital Care Coordination 1.3 Resuscitation Pharmacology, Pharmacokinetics & Vascular Access

2 Chapter 2: Cardiac Arrest and Dysrhythmias

2.1 Adult Cardiac Arrest & ACLS Pharmacotherapy Protocols 2.2 Acute Tachyarrhythmias: Narrow- and Wide-Complex Management 2.3 Symptomatic Bradycardia & Vasoactive Chronotropic Support 2.4 Post-Cardiac Arrest Care & Targeted Temperature Management (TTM)

3 Chapter 3: Shock and Hemodynamic Resuscitation

3.1 Sepsis & Septic Shock: Surviving Sepsis Campaign 2026 Resuscitation 3.2 Cardiogenic & Obstructive Shock, Mechanical Circulatory Support & LVADs 3.3 Hypovolemic & Hemorrhagic Shock Fluid Protocols

4 Chapter 4: Airway Management and Rapid Sequence Intubation (RSI)

4.1 Rapid Sequence Intubation (RSI) Process & Pretreatment Agents 4.2 RSI Induction Agents: Pharmacology, Selection & Dosing 4.3 Neuromuscular Blocking Agents & Post-Intubation Analgosedation

5 Chapter 5: Neurocritical Care and Neurologic Emergencies

5.1 Acute Ischemic Stroke: Thrombolysis & Blood Pressure Control 5.2 Intracranial Hemorrhage & Elevated ICP Pharmacotherapy 5.3 Status Epilepticus: Tiered Emergent Anticonvulsant Therapy 5.4 Traumatic Brain Injury & Spinal Cord Emergencies

6 Chapter 6: Acute Coronary Syndromes and Acute Heart Failure

6.1 Acute Coronary Syndromes: STEMI & NSTE-ACS Pharmacotherapy 6.2 Acute Decompensated Heart Failure & Cardiogenic Pulmonary Edema 6.3 Hypertensive Crises: Emergencies, Urgencies & Target Blood Pressure

7 Chapter 7: Pulmonary and Allergic Emergencies

7.1 Acute Pulmonary Embolism: Risk Stratification & Thrombolytic Therapy 7.2 Severe Asthma Exacerbation & COPD Acute Management 7.3 Anaphylaxis & Severe Allergic Reactions: Acute Epinephrine Protocols

8 Chapter 8: Clinical Toxicology: Approach to Poisoning and Common Overdoses

8.1 Approach to the Poisoned Patient: Poison Centers, Toxidromes, Decontamination & Enhanced Elimination 8.2 Acetaminophen Overdose & N-Acetylcysteine Dosing Strategies 8.3 Salicylate Toxicity & Toxic Alcohol Management (Fomepizole) 8.4 Opioid Toxicity & Sedative-Hypnotic/Alcohol Withdrawal Syndromes 8.5 Beta-Blocker & Calcium Channel Blocker Toxicity (HIET, Calcium, Glucagon)

9 Chapter 9: Toxicology: Specialized Poisonings and Antidotes

9.1 Digoxin, Tricyclic Antidepressants & Anticholinergic Toxicity 9.2 Cyanide, Carbon Monoxide & Organophosphate/Cholinergic Toxins 9.3 Snake and Spider Envenomations & Heavy Metal Chelation 9.4 Additional Antidotes: Methemoglobinemia, Isoniazid, Sulfonylureas, Valproate, Sympathomimetics & LAST

10 Chapter 10: Hemostasis, Anticoagulant Reversal, and Hematology

10.1 DOAC & Warfarin Reversal: Specific Reversal Agents & 4F-PCC 10.2 Heparin-Induced Thrombocytopenia (HIT) & Direct Thrombin Inhibitors 10.3 Sickle Cell Vaso-Occlusive Crises & Acute Chest Syndrome

11 Chapter 11: Endocrine, Electrolyte, and Metabolic Emergencies

11.1 Diabetic Ketoacidosis (DKA) & Hyperosmolar Hyperglycemic State (HHS) 11.2 Severe Electrolyte Emergencies: Hyperkalemia & Hyponatremia 11.3 Endocrine Crises: Thyroid Storm, Myxedema Coma & Acute Adrenal Crisis 11.4 Acute Kidney Injury, Dialyzability & Drug Dosing during RRT

12 Chapter 12: Infectious Diseases and Antimicrobial Stewardship

12.1 Severe Community & Hospital-Acquired Infections in the ED 12.2 Skin & Soft Tissue, STI, and Vector-Borne Emergencies 12.3 ED Antimicrobial Stewardship & Rapid Microbiologic Diagnostics

13 Chapter 13: Special Populations: Pediatrics, Trauma, and Obstetrics

13.1 Pediatric Resuscitation, Status Epilepticus & PALS Pharmacotherapy 13.2 Trauma Pharmacotherapy: Massive Transfusion, TXA, Open Fractures, Tetanus & Burns 13.3 Obstetric & Gynecologic Emergencies: Preeclampsia, Eclampsia & PPH

14 Chapter 14: Medication Safety, ED Operations, and Disaster Preparedness

14.1 ED High-Alert Medications, Error Reporting & Technology Safeguards 14.2 ED Workflow, Transitions of Care & Boarding Patient Management 14.3 Mass Casualty Incidents, CBRNE Countermeasures & Strategic Stockpiles

15 Chapter 15: Biostatistics, Study Design, and Literature Evaluation

15.1 Biostatistics & Hypothesis Testing: Power, Errors & Interpretations 15.2 Clinical Study Designs & Measures of Effect 15.3 Literature Evaluation, Clinical Guidelines & Research Conduct in the ED

16 Chapter 16: Medical Devices, Ventilation, and Medication Delivery

16.1 Mechanical Ventilation, Noninvasive Ventilation & High-Flow Oxygen: What the Pharmacist Must Know 16.2 Vascular Access, Enteral Tubes, Drains & Extravasation Management 16.3 Infusion Pumps, Patient-Owned Devices & Medication Delivery Device Counseling

17 Chapter 17: Organ-System Emergencies: GI, GU, Oncology, Neurology, ENT, Pain, and Psychiatry

17.1 Gastrointestinal & Hepatic Emergencies: GI Bleeding, Cirrhosis Complications, Pancreatitis & Vomiting 17.2 Genitourinary Emergencies: UTI & Pyelonephritis, Renal Colic, Urinary Retention, Priapism & Scrotal Infections 17.3 Oncologic, Immunotherapy & Hematologic Emergencies: Febrile Neutropenia, TLS, Hypercalcemia, irAEs, CAR-T, Hemophilia & TTP 17.4 Headache & Neuromuscular Emergencies: Migraine, Cluster, Myasthenic Crisis, Guillain-Barré & Bell's Palsy 17.5 Ophthalmologic, ENT & Dental Emergencies: Eye Injuries, Angle Closure, Angioedema, Epistaxis, Ear & Throat Infections and Dental Pain 17.6 Acute Pain Management & Procedural Sedation and Analgesia in the ED 17.7 Psychiatric Emergencies: Severe Agitation, Serotonin Syndrome, NMS, Lithium Toxicity & Psychotropic Overdose

18 Chapter 18: Special Populations, Medication Access, and Professional Practice

18.1 Pharmacogenomics, Adverse Drug Events & High-Risk Drug Interactions in Emergency Care 18.2 Special Populations: Older Adults, Extremes of Weight, Pregnancy & Lactation, and Immunocompromised Patients 18.3 Social Determinants of Health, Health Literacy & Medication Access at ED Discharge 18.4 Healthcare Regulations & Standards: FDA, REMS, Bar Coding, DEA, CMS, EMTALA, The Joint Commission, NIOSH & USP 18.5 Formulary & Inventory Management, Drug Shortages, Antidote Stocking & Clinical Decision Support 18.6 Quality Improvement, Practice Standards & Interprofessional Collaboration (Protocols, Teamwork & Debriefing)

6.1 Acute Coronary Syndromes: STEMI & NSTE-ACS Pharmacotherapy

Key Takeaways Explain This Topic AI

Immediate dual antiplatelet therapy (DAPT) for acute coronary syndromes combines chewed non-enteric coated aspirin (162–325 mg) with an oral P2Y12 inhibitor (ticagrelor 180 mg, prasugrel 60 mg, or clopidogrel 300–600 mg) or IV cangrelor.

Prasugrel carries a boxed warning and strict contraindication in patients with a history of stroke or TIA, age ≥75 years, or body weight <60 kg due to excessive fatal intracranial and major bleeding.

Parenteral anticoagulation options include unfractionated heparin (60 units/kg bolus, 12 units/kg/h infusion), enoxaparin (1 mg/kg SC q12h with age and renal adjustments), and bivalirudin for patients with heparin-induced thrombocytopenia.

Nitroglycerin is strictly contraindicated in right ventricular infarction (inferior STEMI with ST-elevation in V4R), hypotension (SBP <90 mmHg), and recent PDE-5 inhibitor use (within 24h for sildenafil/vardenafil or 48h for tadalafil).

When primary PCI cannot be accomplished within 120 minutes of first medical contact for STEMI, weight-based IV tenecteplase should be administered within 30 minutes of emergency department arrival.

Last updated: October 2026

6.1 Acute Coronary Syndromes: STEMI & NSTE-ACS Pharmacotherapy

Note

Independent BCEMP study resource provided by ExamFinch. Content is organized around Board of Pharmacy Specialties (BPS) Emergency Medicine Pharmacy examination specifications.

Pathophysiology & Clinical Spectrum

Acute coronary syndrome (ACS) encompasses a continuum of acute myocardial ischemia triggered by atherosclerotic plaque rupture or erosion. Disruption of the vascular endothelium exposes subendothelial collagen and von Willebrand factor, inducing immediate platelet adhesion via glycoprotein (GP) Ib/IX receptors. Platelet activation triggers the release of thromboxane A2 (TXA2) and adenosine diphosphate (ADP), culminating in conformational activation of platelet surface GP IIb/IIIa receptors and fibrinogen cross-linking. The resulting intraluminal thrombus produces acute coronary luminal compromise:

ST-Segment Elevation Myocardial Infarction (STEMI) : Complete, persistent transmural coronary occlusion requiring immediate reperfusion to prevent transmural myocardial necrosis.

Non-ST-Segment Elevation ACS (NSTE-ACS) : Incomplete, intermittent, or microembolizing occlusion presenting without persistent ST elevations. Subcategorized into Non-ST-Elevation Myocardial Infarction (NSTEMI) (demonstrated by positive cardiac biomarkers such as high-sensitivity cardiac troponin I or T) and Unstable Angina (UA) (ischemic symptoms and electrocardiographic changes without myocardial necrosis biomarkers).

Emergency pharmacotherapy focuses on rapid platelet inhibition, thrombin generation suppression, restoration of myocardial oxygen supply-demand balance, and emergent reperfusion.

Antiplatelet Pharmacotherapy

Dual antiplatelet therapy (DAPT) combining aspirin with a P2Y12 receptor antagonist represents the standard of care across all ACS presentations.

Important

The 2025 ACC/AHA/ACEP/NAEMSP/SCAI ACS guideline (Rao et al.) replaced the separate 2013 STEMI and 2014 NSTE-ACS guidelines. Key points:

Ticagrelor or prasugrel is recommended in preference to clopidogrel for patients with ACS undergoing PCI.

For NSTE-ACS managed without planned invasive evaluation, ticagrelor is recommended. Upstream P2Y12 pretreatment is considered mainly when angiography will be delayed beyond 24 hours.

With fibrinolytic therapy, clopidogrel is the P2Y12 inhibitor studied : 300 mg load if under 75 years, 75 mg with no load at 75 years or older.

DAPT for at least 12 months is the default if bleeding risk is not high. Transitioning to ticagrelor monotherapy 1 month or more after PCI is an accepted bleeding-reduction strategy, with a PPI for patients at GI bleeding risk. ACUTE ACS ANTIPLATELET CASCADE

  • ┌───────────────────────────────────────────────────────────────────────────┐
  • │ Aspirin (162–325 mg non-enteric chewed) ──► Irreversible COX-1 Inhibition │
  • └─────────────────────────────────────┬─────────────────────────────────────┘
  • │
  • ▼
  • ┌───────────────────────────────────────────────────────────────────────────┐
  • │ P2Y12 RECEPTOR INHIBITORS │
  • │ • Ticagrelor (180 mg load): Reversible cyclopentyltriazolopyrimidine │
  • │ • Prasugrel (60 mg load): Irreversible thienopyridine (Avoid if TIA/CVA) │
  • │ • Clopidogrel (300–600 mg load): Irreversible prodrug (CYP2C19 dependent)│
  • │ • Cangrelor (30 mcg/kg IV + 4 mcg/kg/min): Rapid on/off parenteral agent │
  • └───────────────────────────────────────────────────────────────────────────┘
  • Aspirin

Loading Dose : 162 to 325 mg non-enteric coated formulation administered immediately upon ED arrival.

Administration Technique : Must be chewed and swallowed . Chewing promotes rapid buccal and proximal gastric absorption, achieving complete COX-1 suppression and thromboxane A2 inhibition within 15 to 30 minutes. Enteric-coated formulations exhibit erratic, delayed absorption (taking 3 to 4 hours) and must never be swallowed whole in acute presentations.

Maintenance : 81 mg orally once daily indefinitely.

Oral P2Y12 Receptor Inhibitors

Ticagrelor :

Loading Dose : 180 mg orally once.

Maintenance : 90 mg orally twice daily (lowered to 60 mg twice daily after 12 months in high-risk patients).

Pharmacology : Reversible, direct-acting cyclopentyltriazolopyrimidine. Does not require hepatic metabolic conversion. The landmark PLATO trial demonstrated superior reductions in ischemic death and stent thrombosis without excess overall major bleeding compared to clopidogrel.

Adverse Effects & Nuances : Self-limiting dyspnea occurs in 10% to 15% of patients (mediated by adenosine reuptake inhibition; typically benign and distinct from acute pulmonary edema), asymptomatic ventricular pauses, and mild hyperuricemia.

Prasugrel :

Loading Dose : 60 mg orally once.

Maintenance : 10 mg orally once daily (reduced to 5 mg orally once daily if body weight is <60 kg; generally avoid if age ≥75 years).

Pharmacology : Potent, irreversible thienopyridine prodrug requiring a single-step hepatic CYP450 activation (CYP3A4, CYP2B6). In the TRITON-TIMI 38 trial, prasugrel significantly reduced ischemic events and stent thrombosis compared to clopidogrel.

Black Box Warning & Contraindications :

History of prior stroke or TIA : Absolute contraindication due to excess fatal and intracranial hemorrhage causing net clinical harm.

Age ≥75 years : Generally not recommended due to heightened bleeding risk, except in high-risk clinical subsets (diabetes mellitus or prior MI) where 10 mg or 5 mg daily may be considered.

Body weight <60 kg : Increased drug exposure requires dose reduction to 5 mg daily.

Pre-treatment Caution : In NSTE-ACS, prasugrel should only be administered after coronary anatomy is defined at diagnostic angiography (ACCOAST trial demonstrated increased bleeding without ischemic benefit from upstream pre-treatment).

Clopidogrel :

Loading Dose : 300 to 600 mg orally once (600 mg loading dose preferred for primary PCI; 300 mg for fibrinolytic therapy in patients aged ≤75 years; no loading dose for patients aged >75 years undergoing fibrinolysis).

Maintenance : 75 mg orally once daily .

Pharmacology : Second-generation thienopyridine prodrug requiring two-step hepatic bioactivation involving CYP2C19, CYP1A2, and CYP2B6. Subject to significant pharmacogenomic variability due to CYP2C19 loss-of-function alleles (*2, *3) and drug interactions with potent CYP2C19 inhibitors (e.g., omeprazole, esomeprazole).

Intravenous P2Y12 Inhibitor: Cangrelor

Dosing : 30 mcg/kg IV bolus followed immediately by a continuous infusion of 4 mcg/kg/min for at least 2 hours or the duration of PCI (whichever is longer).

Pharmacology : Direct-acting, reversible non-thienopyridine ATP analog. Exhibits instantaneous onset (steady-state platelet inhibition within 2 minutes) and rapid offset (plasma half-life 3 to 6 minutes; normal platelet function restored within 60 minutes of cessation).

Clinical Indications : Indicated for P2Y12-inhibitor-naive patients undergoing PCI, particularly those unable to take oral medications (intubated, sedated, vomiting, receiving therapeutic hypothermia) or those receiving parenteral opioids (morphine, fentanyl) which delay oral P2Y12 absorption by 2 to 4 hours via gastroparesis.

Transition to Oral P2Y12 Inhibitors :

Ticagrelor : 180 mg loading dose may be administered at any time during or immediately upon discontinuation of the cangrelor infusion.

Prasugrel or Clopidogrel : Because cangrelor competitively occupies the P2Y12 receptor, the short-lived active metabolites of thienopyridines cannot bind. Therefore, prasugrel 60 mg or clopidogrel 600 mg must be administered immediately AFTER discontinuing cangrelor, never during the infusion.

Parenteral Anticoagulant Pharmacotherapy

Parenteral anticoagulation is required for all patients with acute coronary syndromes to suppress thrombin generation and prevent catheter-related or coronary thrombosis.

Anticoagulant Dosing in STEMI Dosing in NSTE-ACS Monitoring Parameters & Notes

Unfractionated Heparin (UFH) 60 units/kg IV bolus (max 4,000 units), then 12 units/kg/h (max 1,000 units/h). Primary PCI bolus: 70–100 units/kg. 60 units/kg IV bolus (max 4,000 units), then 12 units/kg/h (max 1,000 units/h). Target aPTT: 1.5–2.0x control (50–70 seconds) or anti-Xa: 0.3–0.7 IU/mL. PCI ACT target: 250–300s (200–250s with GP IIb/IIIa).

Enoxaparin (LMWH) Age <75: 30 mg IV bolus + 1 mg/kg SC (max 100 mg 1st 2 doses), then 1 mg/kg SC q12h. Age ≥75: No bolus; 0.75 mg/kg SC q12h (max 75 mg 1st 2 doses). 1 mg/kg SC q12h (no IV bolus regardless of age). CrCl <30 mL/min: 1 mg/kg SC q24h. PCI additional IV dose: 0.3 mg/kg IV if last SC dose was 8–12h prior.

Bivalirudin 0.75 mg/kg IV bolus, then 1.75 mg/kg/h IV infusion during PCI. 0.1 mg/kg IV bolus, then 0.25 mg/kg/h IV infusion (escalated for PCI). Direct thrombin inhibitor. Preferred alternative in heparin-induced thrombocytopenia (HIT) or high bleeding risk.

Important

For patients with severe renal impairment (CrCl <30 mL/min), unfractionated heparin is the preferred parenteral anticoagulant because it is cleared mainly by saturable endothelial and reticuloendothelial uptake rather than the kidneys, has a short half-life, and is fully reversible with protamine sulfate.

  • Hemodynamic & Symptomatic Adjuncts
  • Nitroglycerin (Sublingual & Intravenous)

Mechanism : Endothelial conversion to nitric oxide stimulates soluble guanylyl cyclase, increasing cyclic GMP and inducing systemic vascular smooth muscle relaxation. At low to intermediate doses, venodilation predominates, reducing right and left ventricular end-diastolic volume (preload reduction) and myocardial oxygen demand while improving subendocardial coronary perfusion.

Administration : Sublingual 0.4 mg every 5 minutes up to 3 doses; intravenous infusion initiated at 5 to 10 mcg/min and titrated by 5 to 20 mcg/min every 3 to 5 minutes based on ischemic chest discomfort and blood pressure.

Strict Contraindications :

Right Ventricular (RV) Infarction : In patients with inferior STEMI (leads II, III, aVF), an emergent right-sided ECG must be evaluated. ST-segment elevation ≥1 mm in lead V4R confirms RV involvement. The ischemic right ventricle is preload-dependent; venodilation precipitates catastrophic drops in cardiac output and profound shock.

Hypotension : Systolic BP <90 mmHg or a drop ≥30 mmHg below baseline.

Marked Bradycardia or Severe Tachycardia : Heart rate <50 bpm or >100 bpm in the absence of heart failure.

Recent PDE-5 Inhibitor Use : Sildenafil or vardenafil within 24 hours, or tadalafil within 48 hours. Co-administration causes synergistic cGMP accumulation leading to severe, treatment-refractory hypotension and cardiac arrest.

Warning

Never administer nitrates to an inferior STEMI patient until a right-sided ECG (V3R/V4R) confirms the absence of right ventricular infarction, and always verify the exact timing of any phosphodiesterase-5 inhibitor ingestion within the preceding 48 hours.

Early Beta-Blockers

Guideline Direction : Oral beta-blocker therapy (e.g., metoprolol tartrate 25 to 50 mg orally every 6 hours or metoprolol succinate daily) should be initiated within the first 24 hours in hemodynamically stable patients without contraindications.

The COMMIT/CCS-2 Trial Pitfall : Routine intravenous beta-blockers must be avoided during initial emergency department presentation. The massive COMMIT/CCS-2 trial demonstrated that early IV beta-blockade reduced reinfarction and ventricular arrhythmias but caused an immediate, significant excess of cardiogenic shock and overall mortality, predominantly on day 1.

Absolute Contraindications to Early Beta-Blockade :

Signs of acute heart failure (pulmonary rales, Killip class II or III).

Evidence of low cardiac output state.

Heightened risk for cardiogenic shock: Age >70 years, systolic BP <120 mmHg, sinus tachycardia >110 bpm or heart rate <60 bpm, and prolonged time from symptom onset.

PR interval >0.24 seconds, second- or third-degree AV block.

Active reactive airway disease or bronchospastic asthma.

  • Reperfusion Strategies in STEMI STEMI REPERFUSION TIMELINE
  • First Medical Contact (FMC)
  • │
  • ├──────────────────────────┬──────────────────────────┐
  • ▼ ▼ ▼
  • PCI Center Transfer to PCI Center PCI Unavailable
  • (FMC-to-Device ≤90 min) (FMC-to-Device ≤120 min) (FMC-to-Device >120 min)
  • │ │ │
  • ▼ ▼ ▼
  • Primary PCI Primary PCI Fibrinolytic Therapy
  • (Door-to-Needle ≤30 min)
  • Primary Percutaneous Coronary Intervention (PCI)

Primary PCI is the preferred reperfusion modality when it can be achieved within ≤90 minutes of FMC at a PCI-capable center, or ≤120 minutes of FMC when interfacility transfer is required.

Fibrinolytic Therapy

When primary PCI cannot be accomplished within 120 minutes of first medical contact, fibrinolytic therapy should be administered within 30 minutes of emergency department arrival (door-to-needle time ≤30 minutes) , provided ischemic symptom duration is ≤12 hours and no absolute contraindications exist.

Tenecteplase (TNK-tPA) : Genetically engineered tissue plasminogen activator with 14-fold greater fibrin specificity, 80-fold greater resistance to PAI-1 and a longer half-life (about 20 to 24 minutes initially, versus under 5 minutes for alteplase), so it is given as a single weight-based IV bolus over 5 seconds:

  • Weight <60 kg : 30 mg IV bolus
  • Weight 60 to <70 kg : 35 mg IV bolus
  • Weight 70 to <80 kg : 40 mg IV bolus
  • Weight 80 to <90 kg : 45 mg IV bolus
  • Weight ≥90 kg : 50 mg IV bolus

Elderly Dose Adjustment : In patients aged ≥75 years , the STREAM trial established that administering a half-dose tenecteplase bolus maintains reperfusion efficacy while significantly reducing intracranial hemorrhage.

Absolute Contraindications to Fibrinolysis :

Any prior intracranial hemorrhage.

Known structural cerebral vascular lesion (e.g., arteriovenous malformation).

Known malignant intracranial neoplasm.

Ischemic stroke within the preceding 3 months (excluding acute stroke within 4.5 hours).

Suspected acute aortic dissection.

Active internal bleeding or bleeding diathesis (excluding menses).

Significant closed-head or facial trauma within the preceding 3 months.

Intracranial or intraspinal surgery within the preceding 2 months.

Severe uncontrolled hypertension unresponsive to emergency therapy (SBP >180 mmHg or DBP >110 mmHg).